S. Salmon

发表

Discrimination between human T and B lymphocytes by computer analysis of digitized data from scanning microphotometry. II. Discrimination and automated classification.

P. Bartels, G. B. Olson, Y. P. Chen, 1978, Acta cytologica.

Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms.

T. Grogan, C. Taylor, S. Salmon, 1990, Blood.

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

S. Salmon, B. Durie, Brian G. M. Durie, 1975, Cancer.

Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms

Charles W. Taylor, T. Grogan, S. Salmon, 1990 .

Immunoglobulin synthesis and tumor kinetics of multiple myeloma.

S. Salmon, 1973, Seminars in hematology.

A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumors

Charles W. Taylor, E. Hersh, P. Fanta, 2001, Cancer Chemotherapy and Pharmacology.

Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.

P. Meltzer, T. Grogan, T. Miller, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term engraftment of fresh human myeloma cells in SCID mice.

T. Grogan, C. Taylor, E. Hersh, 1992, Blood.

Dose response evaluation of adriamycin in human neoplasia

B. Hoogstraten, L. Baker, S. Salmon, 1977, Cancer.

Cellular kinetics in multiple myeloma. A new approach to staging and treatment.

S. Salmon, B. Durie, 1975, Archives of internal medicine.

A phase I/II trial of paclitaxel for non‐Hodgkin's lymphoma followed by paclitaxel plus quinine in drug‐resistant disease

T. Miller, W. Dalton, R. Dorr, 1998, Anti-cancer drugs.

Relation of Osteoclast Activating Factor Production to Extent of Bone Disease in Multiple Myeloma

G. Mundy, S. Salmon, B. Durie, 1981, British journal of haematology.

Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer

S. Jones, S. Salmon, B. Durie, 1975, Cancer.

Evaluation of race as a prognostic factor in multiple myeloma. An ancillary of Southwest Oncology Group Study 8229.

S. Salmon, M. Modiano, P. Villar-Werstler, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil.

T. Grogan, T. Miller, W. Dalton, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of tumor necrosis factor on sensitive and multidrug resistant human leukemia and myeloma cell lines.

P. Meltzer, W. Dalton, P. Scuderi, 1989, Blood.

High speed scintillation autoradiography

S. Salmon, B. Durie, 1975, Science.

Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study.

B. Durie, S. Salmon, J. Files, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The major vault protein (MVP), a new multidrug resistance associated protein, is frequently expressed in multiple myeloma.

L. Rimsza, T. Grogan, W. Dalton, 1999, Leukemia & lymphoma.

P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy

R. Weinstein, T. Grogan, W. Dalton, 1993 .

P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy.

R. Weinstein, T. Grogan, W. Dalton, 1993, Blood.

Immunohistochemical detection and quantitation of p-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation

T. Grogan, W. Dalton, J. Rybski, 1989 .

Cellular kinetics staging, and immunoglobulin synthesis in multiple myeloma.

S. Salmon, B. Durie, 1975, Annual review of medicine.

Relevance of multidrug resistance to rheumatoid arthritis: development of a new therapeutic hypothesis.

W. Dalton, S. Salmon, 1996, The Journal of rheumatology. Supplement.

Amyloid production in human myeloma stem-cell culture, with morphologic evidence of amyloid secretion by associated macrophages.

T. Grogan, S. Salmon, B. Durie, 1982, The New England journal of medicine.

Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation.

T. Grogan, W. Dalton, J. Rybski, 1989, Blood.

Role of gamma globulin for immunoprophylaxis in multiple myeloma.

S. Salmon, D. M. Hayes, B. Samal, 1967, The New England journal of medicine.

Current concepts in the therapy of multiple myeloma.

S. Salmon, W. J. Yount, A. Schilling, 1966, The Medical clinics of North America.

Intermittent high-dose prednisone (NSC-10023) therapy for multiple myeloma.

S. Salmon, R. Shadduck, A. Schilling, 1967, Cancer chemotherapy reports.

Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration.

T. Miller, W. Dalton, C. Appleton, 1991, Journal of the National Cancer Institute.

B-cell neoplasia in man.

S. Salmon, M. Seligmann, 1974, Lancet.

The current status and future prospects of treatment for multiple myeloma.

S. Salmon, B. Durie, 1982, Clinics in haematology.

Comparative in vitro cytotoxicity of cyclophosphamide, its major active metabolites and the new oxazaphosphorine ASTA Z 7557 (INN mafosfamide)

D. Alberts, S. Salmon, J. Einspahr, 2004, Investigational New Drugs.

In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers

D. Alberts, P. Fanta, S. Salmon, 1997, Cancer Chemotherapy and Pharmacology.

Interferons in the treatment of multiple myeloma.

B. Klein, D. Huhn, R. Bataille, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical staging and new therapeutic approaches in multiple myeloma.

S. Salmon, B. Durie, 1978, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

DOXORUBICIN/B.C.N.U. CHEMOTHERAPY FOR MULTIPLE MYELOMA IN RELAPSE

D. Alberts, B. Durie, S. Salmon, 1976, The Lancet.

Synthesis and Metabolism of Bence Jones Protein and Calculation of Tumour Burden in Patients with Bence Jones Myeloma

P. W. Cole, S. Salmon, B. Durie, 1981, British journal of haematology.

Reversal of multidrug resistance in hematologic malignancies with chemosensitizers: laboratory and clinical studies

T. Grogan, T. Miller, W. Dalton, 1994 .

Cytostatic and cytotoxic activity of lymphokine-activated killer cell supernatants

E. Hersh, P. Scuderi, A. Chong, 2005, Cancer Immunology, Immunotherapy.

Tumor growth stimulation in vitro by interferons.

S. Salmon, B. Durie, T. Moon, 1983, European journal of cancer & clinical oncology.

Transplants for multiple myeloma

B. Barlogie, S. Jagannath, G. Tricot, 1995 .

Treatment of multiple myeloma in remission with anticancer drugs having cell cycle specific characteristics.

D. Alberts, S. Salmon, B. Durie, 1977, Cancer treatment reports.

Nitrosoureas in multiple myeloma.

S. Salmon, 1976, Cancer treatment reports.

Human myeloma in vitro colony growth: interrelationships between drug sensitivity, cell kinetics, and patient survival duration.

S. Salmon, B. Durie, L. Young, 1983, Blood.

RAISED SERUM LEVELS OF TUMOUR NECROSIS FACTOR IN PARASITIC INFECTIONS

P. Scuderi, S. Salmon, E. Petersen, 1986, The Lancet.

Cytotoxicity of mitomycin C on clonogenic human carcinoma cells is not enhanced by hypoxia

S. Salmon, C. Ludwig, Y. Peng, 2004, Cancer Chemotherapy and Pharmacology.

Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma.

S. Salmon, Salmon Se, B. Durie, 1980, Blood.

SPONTANEOUS EVOLUTION OF IMMUNE COMPETENCE IN DIGEORGE SYNDROME

B. Hattler, S. Salmon, B. Durie, 1974, Pediatric Research.

Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.

Jason McCoy, Robert A Chapman, Bart Barlogie, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.

B. Barlogie, B. Cheson, S. Jagannath, 1997, Blood.

Efficacy of prednisone in refractory multiple myeloma and measurement of glucocorticoid receptors

E. Thompson, S. Salmon, H. Pierce, 2004, Investigational New Drugs.

Prognostic correlation of plasma cell acid phosphatase and beta-glucuronidase in multiple myeloma: a Southwest Oncology Group study.

J. Crowley, S. Salmon, J. Crowley, 1991, Blood.

Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy: A southwest oncology group study

R. Hartsock, F. Morrison, S. Jones, 1983, Cancer.

Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients.

J. Crowley, B. Barlogie, T. Grogan, 2002, Blood.

Evaluation of topotecan in resistant and relapsing multiple myeloma: a Southwest Oncology Group study.

J. Crowley, E. Kraut, S. Salmon, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining.

T. Grogan, W. Dalton, S. Salmon, 1989, Journal of the National Cancer Institute.

Serum can inhibit reversal of multidrug resistance by chemosensitisers.

W. Dalton, M. Lehnert, S. Salmon, 1996, European journal of cancer.

Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer.

T. Grogan, T. Miller, W. Dalton, 1991, Blood.

Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model.

W. Dalton, M. Lehnert, D. Roe, 1991, Blood.

New Therapeutic Approaches to Myeloma

W. Dalton, S. Salmon, T. Landowski, 2004 .

multiple myeloma patients Maintenance therapy with alternate-day prednisone improves survival in

B. Barlogie, T. Grogan, S. Salmon, 2013 .

High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial.

B. Barlogie, D. Vesole, S. Salmon, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study.

J. Crowley, J. Crowley, S. Balcerzak, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.

T M Grogan, B. Barlogie, T. Grogan, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expansion of the growth fraction in multiple myeloma with alkylating agents.

S. Salmon, S. Salmon, 1975, Blood.

Phase II study of Fludarabine Phosphate in multiple myeloma

M. Grever, J. Crowley, E. Kraut, 1990, Investigational New Drugs.

Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study.

S. Salmon, B. Durie, A. Haut, 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

cDNA microarray analysis of multidrug resistance: doxorubicin selection produces multiple defects in apoptosis signaling pathways.

M. Kunkel, B. Futscher, S. Salmon, 2001, The Journal of pharmacology and experimental therapeutics.

Cell kinetic analysis of human tumor stem cells.

S. Salmon, B. Durie, 1980, Progress in clinical and biological research.

Kinetics of tumor growth and regression in IgG multiple myeloma.

S. Salmon, S E Salmon, P. Sullivan, 1972, The Journal of clinical investigation.

Combination chemotherapy for advanced breast cancer utilizing vincristine, adriamycin, and cyclophosphamide (VAC)

S. Jones, S. Salmon, J. Rainey, 1979, Cancer.

Phase II trial of 4′-deoxydoxorubicin (esorubicin) in hormone resistant prostate cancer

H. Garewal, S. Salmon, T. Braich, 2004, Investigational New Drugs.

Increased peripheral blood leukocyte cytotoxic activity in cancer patients during the continuous intravenous administration of recombinant human tumor necrosis factor

E. Hersh, P. Scuderi, S. Salmon, 2004, Journal of Clinical Immunology.

Effects of suramin on in vitro growth of fresh human tumors.

C. Taylor, P. Fanta, S. Salmon, 1992, Journal of the National Cancer Institute.

Addition of cisplatin and bleomycin to vincristine-carmustine-doxorubicin-prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study.

S. Salmon, R. Alexanian, A. Haut, 1984, Cancer treatment reports.

Comparative trial of low‐dose adriamycin plus cyclophosphamide with or without additive hormonal therapy in advanced breast cancer

S. Jones, S. Salmon, Richard Lloyd, 1979, Cancer.

“PARANEOPLASTIC” SYNDROMES ASSOCIATED WITH MONOCLONAL LYMPHOCYTE AND PLASMA CELL PROLIFERATION *

S. Salmon, 1974 .

Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study.

B. Cheson, C. Coltman, L. Hutchins, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hemopoietic stem cell transplants for multiple myeloma.

B. Barlogie, S. Jagannath, G. Tricot, 1994, Oncology.

Drug resistance in myeloma: mechanisms and approaches to circumvention.

W. Dalton, S. Salmon, 1992, Hematology/oncology clinics of North America.

The nature of cells generating human myeloma colonies in vitro

A. Hamburger, S. Salmon, Maryanne Kim, 1979, Journal of cellular physiology.

Schedule dependent synergism of vinblastine (VLB) and cloned leukocyte interferon A (IFL-rA)

D. Alberts, M. Aapro, S. Salmon, 1981 .

for Previously Untreated Multiple Myeloma Superiority of Tandem Autologous Transplantation Over Standard Therapy

B. Barlogie, B. Cheson, S. Jagannath, 2013 .

Inhibition of intracellular Ca2+ signalling, cytotoxicity and antitumor activity of the herbicide oryzalin and its analogues

G. Powis, R. Abraham, A. Gallegos, 1997, Cancer Chemotherapy and Pharmacology.

In vitro evaluation of chemosensitizers for clinical reversal of P-glycoprotein-associated Taxol resistance.

W. Dalton, M. Lehnert, S. Salmon, 1993, Journal of the National Cancer Institute. Monographs.

Phase II study of fludarabine phosphate in multiple myeloma. A Southwest Oncology Group study.

M. Grever, E. Kraut, S. Salmon, 1990, Investigational new drugs.

Immunoquantitation of free light chain immunoglobulins: applications in multiple myeloma.

P. W. Cole, S. Salmon, B. Durie, 1978, Journal of immunological methods.

Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs.

D. Alberts, A. Hamburger, S. Salmon, 1978, The New England journal of medicine.

Local-regional recurrence in breast cancer after mastectomy and adriamycin-based adjuvant chemotherapy: evaluation of the role of postoperative radiotherapy.

J. Cassady, S. Salmon, S. Salmon, 1989, International journal of radiation oncology, biology, physics.

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

N. Munshi, E. Crawford, V. Roy, 2001, The New England journal of medicine.

The role of radionuclides in clinical oncology.

Stephen E. Jones, S. Salmon, S. Jones, 1976, Seminars in nuclear medicine.

Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia.

W. Dalton, S. Salmon, R. Dorr, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A southwest oncology group study on the use of a human tumor cloning assay for predicting response in patients with ovarian cancer

R. Kronmal, D. V. Von Hoff, S. Salmon, 1991, Cancer.

A hypo-osmotic medium to disaggregate tumor cell clumps into viable and clonogenic single cells for the human tumor stem cell clonogenic assay.

A. Leibovitz, R. Liu, C. Hayes, 1983, International journal of cell cloning.

Effects of granulocyte-macrophage colony-stimulating factor on in vitro growth of human solid tumors.

S. Salmon, S. Salmon, R. Liu, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Polyamines as predictors of success and failure in cancer chemotherapy

S. Salmon, D. Russell, B. Durie, 1975, The Lancet.

Indium-111 bleomycin tumor scanning in lymphoma.

S. Salmon, S. Jones, S. Salmon, 1975, Medical and pediatric oncology.

In vitro assay for sensitivity to anticancer drugs.

S. Salmon, S. Salmon, 1985, Hospital practice.